Table 4.
Patients and GAs | Pretest endocrine therapy | Response |
---|---|---|
#2 D538G +2 GAs | Exemestane + everolimus | SD for 6 months |
#3 L536_D538>P +5 GAs | Exemestane + everolimus | SD for 8 months |
#4 Y537C +8 GAs | Fulvestrant | SD for 8 months |
#5 D538G +3 GAs | Exemestane + everolimus | SD for 12 months |
#8 Y537N +7 GAs | Fulvestrant | PD |
#10 Y537S +1 GA | Tamoxifen | PD |
#12 Y537S +4 GA | Fulvestrant | PD |
| ||
Patients and GAs | Post-test endocrine therapy | Response |
| ||
#17 Y537S +8 GAs | Exemestane + everolimus | PD |
#21 Y537S +3 GAs | Exemestane + everolimus | PD |
#22 D538G +4 GAs | Exemestane + everolimus | SD for 18 months |
#23 D538G +4 GAs | Exemestane + everolimus | SD for 6 months |
#30 Y537S +2 GAs | Fulvestrant | PD |
#31 D538G +0 GA | Fulvestrant | PD |
Abbreviations: GA, genomic alteration; PD, progression of disease; SD, stable disease.